Discovery and validation of small-molecule heat-shock protein 90 inhibitors through multimodality molecular imaging in living subjects

Carmel T. Chan\textsuperscript{a,b,c}, Robert E. Reeves\textsuperscript{a,b,c}, Ron Geller\textsuperscript{d}, Shahriar S. Yaghoubi\textsuperscript{a,b,c}, Aileen Hoehne\textsuperscript{a,b,c}, David E. Solow-Cordero\textsuperscript{a}, Gabriela Chiosis\textsuperscript{a}, Tarik F. Massoud\textsuperscript{g}, Ramasamy Paulmurugan\textsuperscript{a,b,c}, and Sanjiv S. Gambhir\textsuperscript{a,b,c,h,i,1}

\textsuperscript{a}Department of Radiology, \textsuperscript{b}Molecular Imaging Program at Stanford (MIPS), \textsuperscript{c}Bio-X Program, \textsuperscript{d}Department of Biological Sciences, and \textsuperscript{1}Stanford High-Throughput Bioscience Center, Department of Chemical and System Biology, Stanford University School of Medicine, Stanford, CA 94305; \textsuperscript{e}Department of Molecular Pharmacology and Chemistry, Memorial Sloan-Kettering Cancer Center, New York, NY 10065; \textsuperscript{f}Department of Radiology, University of Cambridge, Cambridge CB2 2QQ, United Kingdom; and \textsuperscript{g}Department of Bioengineering and Department of Materials Science and Engineering, Stanford University, Stanford, CA 94305

Edited* by Michael E. Phelps, University of California, Los Angeles, CA, and approved July 16, 2012 (received for review April 6, 2012)

Up-regulation of the folding machinery of the heat-shock protein 90 (Hsp90) chaperone protein is crucial for cancer progression. The two Hsp90 isoforms (α and β) play different roles in response to chemotherapy. To identify isoform-selective inhibitors of Hsp90 (α/β)/cochaperone p23 interactions, we developed a dual-luciferase (Renilla and Firefly) reporter system for high-throughput screening (HTS) and monitoring the efficacy of Hsp90 inhibitors in cells and live mice. HTS of a 30,176 small-molecule chemical library in cell culture identified a compound, N-(5-methylisoxazol-3-yl)-2-[4-(thiophen-2-yl)-6-(trifluoromethyl)pyrimidin-2-yl]acetamide (CP9), that binds to Hsp90α/β and displays characteristics of Hsp90 inhibitors, i.e., degradation of Hsp90 client proteins and inhibition of cellular proliferation, glucose metabolism, and thymidine kinase activity, in multiple cancer cell lines. The efficacy of CP9 in disrupting Hsp90α/β/p23 interactions and cell proliferation in tumor xenografts was evaluated by non-invasive, repetitive Renilla luciferase and Firefly luciferase imaging, respectively. At 38 h post-treatment (80 mg/kg × 3, i.p.), CP9 led to selective disruption of Hsp90α/β/p23 as compared with Hsp90β/p23 interactions. Small-animal PET/CT in the same cohort of mice showed that CP9 treatment (43 h) led to a 40% decrease in \textsuperscript{18}F-fluorodeoxyglucose uptake in tumors relative to carrier control-treated mice. However, CP9 did not lead to significant degradation of Hsp90 client proteins in tumors. We performed a structural activity relationship study with 62 analogs of CP9 and identified A17 as the lead compound that outperformed CP9 in inhibiting Hsp90α/β/p23 interactions in cell culture. Our efforts demonstrated the power of coupling of HTS with multimodality molecular imaging and led to identification of Hsp90 inhibitors.

Geldanamycin-based Hsp90 inhibitors (8), purine scaffold–(9–16), pyrazole scaffold–(17), and radicicol-based Hsp90 inhibitors (18, 19), and other compounds are currently in preclinical and/or phase I/II clinical trials (20–22). Despite the diversity of Hsp90 inhibitors reported, inhibitors with better clinical therapeutic efficacy and reduced toxicity are needed. Until now, methods for identifying of Hsp90 inhibitors have been limited to in vitro analyses (13, 23, 24) and phenotypic assays that examine the downstream effects of the Hsp90 inhibition (9, 14, 15, 18). Small-animal PET (25, 26), MRI (27), and ultrasound (28) have been used to monitor the efficacy of Hsp90 inhibitors in mice. However, it was not possible to decipher the contribution of each Hsp90 isoform (α and β) in determining sensitivity to Hsp90 inhibitors, because both isoforms are expressed in cancer cells but play different roles in response to chemotherapy (29).

We previously monitored the efficacy of different Hsp90 inhibitors in disrupting isoform-specific interactions between Hsp90 (α/β) and p23 in intact cells in cell culture and in live mice using a genetically encoded split Renilla luciferase (RL) complementation system (Fig. 1A) (30). This system is useful for identifying Hsp90 inhibitors because (i) the potency of the Hsp90 inhibitors in disrupting signals from Hsp90α/β/p23 interactions correlates with their binding affinities for cellular Hsp90; (ii) the interaction of each Hsp90 isoform (α or β) with p23 can be monitored individually; (iii) RL does not require ATP for its activity and thus facilitates the screening of inhibitors that target the ATP-binding pocket of Hsp90; (iv) the same reporter cells can be used for high-throughput screening (HTS) in cell culture followed by dynamic monitoring of Hsp90α/β/p23 interactions in response to lead compounds in living mice; and (v) the split RL complementation system in combination with other clinical imaging modalities such as PET allows monitoring of the downstream effects of Hsp90 inhibitors.

To accelerate the development of small-molecule Hsp90 inhibitors, we incorporated multimodality molecular imaging into HTS of an uncharacterized chemical library. We successfully identified and monitored the efficacy of a class of...
Results

HTS of Modulators of Hsp90(α/β)/p23 Interactions in Cell Culture. The initial assay development was performed using the Library of Pharmacologically Active Compounds (LOPAC) (31), with 293T human kidney cancer cells expressing the Hsp90α/p23 or Hsp90β/p23 split RL reporters (30). Baseline bioluminescence imaging (BLI) signals were determined before the addition of LOPAC compounds. The known Hsp90 inhibitor PU-H71 (11) was used a positive control. Twenty compounds were identified with greater than 50% inhibition of BLI signals relative to carrier control-treated cells at 24 h (Fig. 1B). Our initial screen demonstrated that our assay conditions were optimal for discovery of isoform-selective Hsp90(α/β)/p23 modulators in intact cells.

We proceeded to identify Hsp90 inhibitors using a commercially available small-molecule chemical compound library with 30,176 compounds (8.3 μM each) with unknown targets and molecular mechanisms (Fig. 1C). IC_{50} values were determined for the 317 compounds that led to greater than 45% inhibition of BLI signals relative to carrier control-treated cells. Inhibition of cell proliferation at 20 μM was determined, and toxic compounds were eliminated. The IC_{50} values for inhibition of BLI signals and cell proliferation by the top 19 compounds with the lowest IC_{50} values for inhibition of Hsp90α/p23 interactions are shown in Table 1, and their structures are shown in Table S1. To determine if any of the top compounds are nonspecific RL inhibitors, 293T cells stably expressing full-length RL were treated with the compounds for different periods of time at levels 10-fold higher than their respective IC_{50} for inhibition of Hsp90α/p23 interactions (Fig. 2A). Compounds that led to greater than 20% inhibition of RL signals relative to carrier control-treated cells were eliminated (Fig. S1).

Efficacy of Lead Compounds in Inhibiting Hsp90 Chaperone Activities. Hsp90 inhibitors lead to degradation of Hsp90 client proteins in cancer cells (20, 32, 33). We initially focused on the two compounds with the greatest inhibition of Hsp90α/p23 BLI signals, CP1 and CP18, and on CP9, N-(5-methylisoxazol-3-yl)-2-(4-thiophen-2-yl)-6-(trifluoromethyl)pyrimidin-2-yl)hexafluoracetamide, which was more selective for inhibition of Hsp90α/p23 BLI signals than for inhibition of Hsp90β/p23 interactions (Table 1 and Fig. 2B–D). To determine if these compounds led to degradation of Hsp90 client proteins, 293T cells were treated with CP1, CP9, and CP18, and the expression of phosphorylated Akt relative to total Akt (pAkt/total Akt) and Raf-1 were determined by Western blotting (Fig. 3A). Cells treated with PU-H71 served as a positive control. CP1 did not decrease the levels of any of the three Hsp90 client proteins significantly; CP9 was more effective than CP18 in degrading the pAkt, total Akt, and Raf-1 (Fig. 3A). PU-H71 decreased levels of Raf-1, pAkt, and total Akt, as expected. The disruption of endogenous Hsp90α(β)/p23 interactions by CP9 and CP18 was confirmed by coimmunoprecipitation (Fig. 3B). Based on our results, we focused our efforts on further characterization of CP9 because of its efficacy as an Hsp90 inhibitor.

CP9 led to various levels of degradation of pAkt/total Akt and Raf-1 in multiple cancer cell lines, including lung (175), liver (Huh-7), and breast (BT474) cancer cells, but had no effect on the expression of the Hsp90 client proteins in normal mouse embryonic fibroblasts (MEFs) (Fig. S2A). To confirm the direct response experiment (0.3–20 μM) (Table 1). Toxic compounds were eliminated. Numbers within parentheses denote the number of compounds at each stage during the screening.
binding of CP9 to Hsp90(α/β), an in vitro competitive binding assay was performed using purified Hsp90α/β and the radiolabeled Hsp90 inhibitor [3H]17-allylamino-17-demethoxygeldanamycin ([3H-17-AAG]). Hsp90 proteins were prebound with CP9 or cold 17-AAG as a control before incubation with [3H-17-AAG]. Unbound [3H-17-AAG] was removed, and the amount of [3H-17-AAG] bound to the Hsp90 proteins was determined. If CP9 binds to Hsp90 (either in the same N-terminal ATP pocket or in other portions of Hsp90 that are involved in binding 17-AAG), that binding will reduce the amount of [3H-17-AAG] bound to Hsp90. Fig. 3C shows that CP9 reduced the binding of [3H-17-AAG] to purified Hsp90α by about 50% (P < 0.05) but did not affect the binding to Hsp90β significantly (P > 0.05). To confirm cellular Hsp90 as the target of CP9, we performed uptake studies in HT29 cells using [3H-17-AAG]. PU-H71 was used as a positive control. CP9 led to a dose-dependent decrease in the uptake of [3H-17-AAG] with a maximum reduction of 30% relative to carrier control-treated cells (P < 0.05) (Fig. 3D).

### Table 1. Effect of the lead compounds CP1–CP19 on inhibition of Hsp90α/p23 and Hsp90β/p23 interactions and cell proliferation

<table>
<thead>
<tr>
<th>Compound</th>
<th>IC50 (Hsp90α/p23) (µM)*</th>
<th>IC50 (Hsp90β/p23) (µM)*</th>
<th>% inhibition cell proliferation (20 µM)‡</th>
</tr>
</thead>
<tbody>
<tr>
<td>CP1</td>
<td>0.2</td>
<td>0.5</td>
<td>44</td>
</tr>
<tr>
<td>CP2</td>
<td>0.8</td>
<td>2.4</td>
<td>45</td>
</tr>
<tr>
<td>CP3</td>
<td>1.2</td>
<td>1.6</td>
<td>33</td>
</tr>
<tr>
<td>CP4</td>
<td>1.4</td>
<td>1.7</td>
<td>46</td>
</tr>
<tr>
<td>CP5</td>
<td>1.4</td>
<td>3.1</td>
<td>35</td>
</tr>
<tr>
<td>CP6</td>
<td>1.8</td>
<td>2.8</td>
<td>43</td>
</tr>
<tr>
<td>CP7</td>
<td>1.9</td>
<td>2.9</td>
<td>45</td>
</tr>
<tr>
<td>CP8</td>
<td>2.7</td>
<td>6.0</td>
<td>32</td>
</tr>
<tr>
<td>CP9</td>
<td>3.2</td>
<td>15.3</td>
<td>29</td>
</tr>
<tr>
<td>CP10</td>
<td>1.2</td>
<td>2.4</td>
<td>11</td>
</tr>
<tr>
<td>CP11</td>
<td>1.4</td>
<td>2.3</td>
<td>10</td>
</tr>
<tr>
<td>CP12</td>
<td>1.4</td>
<td>2.4</td>
<td>21</td>
</tr>
<tr>
<td>CP13</td>
<td>2.1</td>
<td>3.3</td>
<td>27</td>
</tr>
<tr>
<td>CP14</td>
<td>2.1</td>
<td>8.1</td>
<td>10</td>
</tr>
<tr>
<td>CP15</td>
<td>2.3</td>
<td>5.7</td>
<td>27</td>
</tr>
<tr>
<td>CP16</td>
<td>2.5</td>
<td>4.0</td>
<td>2</td>
</tr>
<tr>
<td>CP17</td>
<td>3.9</td>
<td>17.5</td>
<td>13</td>
</tr>
<tr>
<td>CP18</td>
<td>0.07</td>
<td>0.04</td>
<td>55</td>
</tr>
<tr>
<td>CP19</td>
<td>0.3</td>
<td>0.8</td>
<td>50</td>
</tr>
</tbody>
</table>

*IC50 was defined as the concentration of the compound required to inhibit bioluminescence signals by 50%, relative to carrier control-treated 293T cells stably expressing Hsp90α/p23 split RL reporters.

‡IC50 was defined as the concentration of the compound required to inhibit bioluminescence signals by 50%, relative to carrier control-treated 293T cells stably expressing Hsp90α/p23 split RL reporters.

§Inhibition of 293T cells stably expressing Hsp90α/p23 split RL reporters by each compound at 20 µM was determined by Cell Titer-Blue assay as described in Materials and Methods.

**CP9 Inhibits Cell Proliferation, Glucose Metabolism, and Mammalian Thymidine Kinase Activities in Multiple Cancer Cell Lines.** To determine if CP9 also inhibits cell proliferation, 2008 ovarian cancer cells, 293T cells, U87-MG glioblastoma cells, and 1975 cells were treated with different concentrations of CP9, and cell proliferation was monitored. CP9 was more effective than PU-H71 and 17-AAG in inhibiting proliferation of U87-MG and 1975 cells but not of 293T and 2008 cells (Fig. 4A). Because CP9 led to a decrease in pAkt (Fig. 3A and Fig. S2A), we expected it to inhibit glucose metabolism (34, 35), as monitored by cell-uptake studies with [3H]fluorodeoxyglucose ([3H-FDG]) (Fig. 4B) (36). PU-H71 was used as a positive control. To determine the specificity of CP9 in inhibiting glucose metabolism, normal MEF cells were used as a control. CP9 decreased [3H-FDG] uptake in the cancer cells without significantly affecting uptake in MEFs. Likewise, CP9 inhibits uptake of [3H]3-fluorodeoxy-thymidine ([3H-FLT]) (a surrogate for thymidine kinase activity in mammalian cells) in cancer cell lines but not in normal MEFs (Fig. S2B). Collectively, our data show that CP9 binds to Hsp90 and leads specifically to degradation of Hsp90 client proteins and inhibition of glucose metabolism, thymidine kinase activity, and cell proliferation in cancer cells.

**Noninvasive Monitoring of Disruption of Hsp90(α/β)/p23 Interactions in Live Mice by CP9.** To monitor the inhibition of Hsp90(α/β)/p23 interactions by CP9 in live mice by BLI, we introduced a second reporter, FL-EGFP, into the 293T cells stably expressing Hsp90(α/β)/p23 split RL reporters (hereafter, 293T(α/β)-FG cells). We chose FL imaging because of its high sensitivity and the ease of sequentially performing FL and RL imaging (37, 38). Baseline RL and FL signals in each implanted tumor were determined.
Based on our experience with Hsp90 inhibitors (30), we initially tested CP9 (80 mg/kg) in mice (n = 5) by i.p. injection, with four doses delivered immediately after and 16, 24, and 49 h after baseline imaging (Fig. 5A). An equal volume of DMSO was injected into the carrier control-treated group (n = 5) (Fig. 5B). Mice treated with 75 mg/kg PU-H71 (n = 2) served as positive controls. Mice were reimaged for Hsp90(α/β)/p23 split reporters and cell proliferation via RL (Fig. 5B, Left) and FL (Fig. 5B, Right) imaging at the time points indicated. To account for the effect of cell number on Hsp90(α/β)/p23 interactions, RL signals were normalized to FL signals for each tumor at each time point, before normalization to signal at time 0 h.

CP9 treatment led to the inhibition of RL signals in tumors bearing Hsp90α/p23 (left flank) and Hsp90β/p23 (right flank) xenografts, relative to time 0 h (Fig. 5A). Normalization of RL signals for cell number shows that CP9 inhibits Hsp90α/p23 interactions in tumor xenografts (P < 0.05 at 38 h vs. carrier control-treated mice) (Fig. 5C). CP9 was less effective in inhibiting Hsp90β/p23 interactions (P > 0.05 at both time points vs. carrier control-treated mice) (Fig. 5D). At 62 h after CP9 treatment, the RL/FL ratios in Hsp90α(β)/p23 xenografts were similar to those in carrier control-treated mice (P > 0.05). Our data are consistent with selectivity of CP9 in binding to Hsp90α and inhibiting Hsp90α/p23 BLI signals in cell culture, relative to Hsp90β/p23.

**CP9 Led to Inhibition of Glucose Metabolism in 293T Xenografts as Shown by Small-Animal [18F]Fluorodeoxyglucose PET/CT Imaging.** [18F]Fluorodeoxyglucose ([18F-FDG]) PET/CT has been used routinely for repetitive and noninvasive monitoring of chemotherapy responses in small animals and in humans (39, 40). Because CP9 inhibits glucose metabolism in cancer cells (Fig. 4B), we monitored its effect in tumor xenografts by small-animal [18F-FDG] PET/CT, using the same cohort of mice used for BLI (Fig. 5). Baseline [18F-FDG] uptake was determined before treatment with carrier control or CP9 (80 mg/kg) (Fig. 6A). The [18F-FDG] uptake in each tumor site relative to the maximum percent injected dose per gram (maximum %ID/g) was determined upon normalization of injected dose (41). In carrier control-treated mice, [18F-FDG] uptake in 293T tumors expressing Hsp90(α/β)/p23 RL reporters (n = 8) increased by 37 ± 18% at 43 h (Fig. 6B). On the other hand, [18F-FDG] uptake in CP9-treated tumors (n = 10) decreased by 16 ± 9% (P < 0.005 relative to carrier control-treated mice). Therefore, CP9 inhibits glucose metabolism in tumor xenografts in live mice. We also analyzed the [18F-FDG] uptake in the brains of mice using CT images to delineate boundaries. Relative to day 0, the maximum %ID/g of [18F-FDG] uptake was 114 ± 11% in mice treated with carrier and 99 ± 4% in mice treated with CP9 (Fig. 6C). There was no statistical difference between the two groups (P > 0.05). Furthermore, there were no significant decreases in weight in CP9-treated mice compared with carrier control-treated mice at 43 h (P > 0.05). Thus, our
at 62 h after CP9 treatment, which did not show any significant
activity relationship (SAR) study using 62 analogs of
α-1 microgram/p23 in intratumoral concentrations for inhibiting Hsp90 (α/β)/p23 interactions and subsequently degrading Hsp90 client proteins (Fig. 7D). Despite this outcome, we have established a SAR study platform that allows rapid screening and evaluation of more potent CP9 analogs, first in cell culture and subsequently in live mice.

Discussion
In the current work we successfully coupled multimodality molecular imaging into HTS and discovered a class of 2-([6-(trifluoromethyl)pyrimidin-2-yl]thio)acetamide–based Hsp90 inhibitors. We used a dual RL/FL reporter system for monitoring isoform-selective Hsp90(α/β)/p23 interactions and cell proliferation in intact cells. Among the three lead compounds, we focused on CP9 rather than CP1 and CP18 because it was more potent in degrading Hsp90 client proteins including Raf-1, pAkt, and total Akt (Fig. 2A) as well as in disrupting Hsp90(α/β)/p23 interactions (Fig. 2B). Furthermore, CP9 exhibits selectivity in binding to pu-

Ex Vivo Analyses of the Efficacy of CP9 in Disrupting Hsp90 Client Proteins. To determine if the inhibition of Hsp90(α/β)/p23 interactions also leads to degradation of Hsp90 client proteins in mice, tumors were excised after PET/CT imaging to analyze the expression of pAkt/total Akt and Raf-1 in tumor lysates. Fig. 6D shows that CP9 treatment did not lead to significant degradation of Hsp90 client proteins relative to carrier control-treated mice (P > 0.05). This observation is consistent with our imaging results at 62 h after CP9 treatment, which did not show any significant differences in Hsp90(α/β)/p23 interactions in CP9-treated and carrier control-treated mice (Fig. 5 C and D).

Evaluation of Efficacy of Structural Analogs of CP9 in Disrupting Hsp90(α/β)/p23 Interactions and Degrading Hsp90 Client Proteins. In attempt to improve the efficacy of CP9, we performed a structure–activity relationship (SAR) study using 62 analogs of CP9 with different modifications (Table S2). Their effects on Hsp90(α/β)/p23 interactions and cell proliferation in stable 293T (α/β)-FG cells were monitored by sequential RL (Fig. S3A) and FL imaging. CP9, PU-H71, and 17-AAG were used as positive controls. Compared with the parent compound CP9, the analogs A14 and A17 led to similar inhibition of Hsp90α(β)/p23 interactions (Fig. S3B, diamonds and squares, respectively). Time–dose–response curves were established for the top 13 analogs with the lowest IC50 values for inhibition of Hsp90α(β)/p23 interactions (Fig. S4A).

When we compared derivatives of CP9 with different R3 substitutions (A1–16, A18–31, A35, A37, A39, A42–44, A46, A47, A49, A51, A53, A55, A56, and A59–62), we found that an aromatic moiety is required and that aliphatic substitution led to diminished efficacy in disrupting Hsp90(α/β)/p23 interactions. A single small ortho substitution on the aromatic ring (as in A14 and A23) and methyl substitution in the meta position (A29 and A61) were tolerated. In CP9 analogs with various R1 substitutions (A17, A45, A48, A50, and A57), a five-member aromatic ring seems to be required for binding; analogs containing phenyl rings with various substitutions in the R2 position exhibited lower activity. Only replacement of the thiophen moiety in CP9 by a furanyl substitution (A17) was tolerated and led to higher potency. Methyl substitution in the R3 position was advantageous: A34 and A50 tend to have higher affinity than A40 and A45, respectively.

The best analogue with the lowest IC50 for inhibition of Hsp90α(β)/p23 interactions was A17, which reduced the IC50 for the inhibition of Hsp90α(β)/p23 signals by threefold compared with CP9 (0.15 vs. 0.45 μM) and which had a twofold-lower IC50 for growth inhibition (Fig. 7A). To determine if the reduction in IC50 for Hsp90α(β)/p23 interactions makes A17 a more efficacious inhibitor of Hsp90, 293T-FG cells were treated with CP9 and A17. PU-H71 and 17-AAG were used as positive controls. A17 was more effective than CP9 in disrupting pAkt/total Akt and Raf-1 (Fig. S4B). Because CP9 and its analogs inhibit Hsp90(α/β)/p23 interactions and lead to the degradation of Hsp90 client proteins, we have identified a class of Hsp90 inhibitors. Because A17 has a lower partition coefficient than CP9 (2.8 vs. 4.1), it may be more hydrophilic with less nonspecific binding of serum proteins and better bioavailability in tumors (42). Contrary to cell-culture results, treatment with A17 did not lead to significant decreases in Hsp90α/β)/p23 interactions in tumor xenografts as compared with carrier control-treated mice using the same dosing regimen (P > 0.05 vs. carrier control-treated mice) (Fig. 7B and C), perhaps because the bioavailability of A17 led to insufficient intratumoral concentrations for inhibiting Hsp90 (α/β)/p23 interactions and subsequently degrading Hsp90 client proteins (Fig. 7D).
CP9 as a 2-[(6-(Trifluoromethyl)Pyrimidin-2-yl)Thio]Acetamide–Based Hsp90 Inhibitor. CP9 competes with \(^{3}H\)-17-AAG for binding to purified Hsp90(α/β), reduces uptake of \(^{3}H\)-17-AAG in intact HT29 cancer cells, and disrupts Hsp90(α/β)/p23 interactions in intact 293T cells (Fig. 3). Our data indicated that CP9 binds to Hsp90. CP9 treatment leads to the degradation of Hsp90 client proteins and inhibition of glucose metabolism, mammalian thymidine kinase, and cell proliferation in multiple cancer cell lines. The inhibition of Hsp90 chaperone activities is species for cancer cells, because CP9 had no effect on normal MEFs. The small chemical library that contains CP9 was used by other investigators in bioassays that were not specifically designed for monitoring Hsp90(α/β)/p23 interactions. Targets that were reported in PubChem (http://pubchem.ncbi.nlm.nih.gov/) to be affected by CP9 include \(\beta\)-adrenergic receptor kinase 1, poly-pyrimidine tract-binding protein 1α, and 5-hydroxytryptamine receptor 1E. It has been reported in PubChem that CP9 inhibits proliferation, protein assembly, and kinase activities in different cancer cell lines. Because Hsp90 is involved in the regulation of kinases, receptors, and protein binding/folding, our data are consistent with others who have reported the downstream effects of CP9 (43).

Both Hsp90 isoforms (α and β) are expressed in cancer cells, but Hsp90β is constitutively expressed, whereas the expression of Hsp90α is highly inducible during stress and drug treatment (29, 44). Using our genetically encoded split Renilla reporter system, we were able to decipher the individual contributions of each isoform in determining the sensitivity of Hsp90 inhibitors. It was reported that the transcription of MDR1 is regulated by HSF-1, which in turn is regulated by Hsp90α (45). To determine the biological significance of CP9 selectivity in inhibiting Hsp90α/p23 interactions, we used V79 lung cancer cells and V79/ADR cells that overexpress multidrug-resistant protein and are insensitive to growth inhibition by doxorubicin (DOX). V79 and V79/ADR cells were treated with DOX alone or in the presence of CP9. In V79 cells that do not express MDR-1, the sensitivity to DOX was not affected by CP9 (Fig. 8A). On the other hand, the addition of CP9 sensitized V79/ADR cells to DOX, as shown by the decrease in cell proliferation relative to treatment with DOX alone (Fig. 8B). Similar results were observed with the known Hsp90 inhibitor PU-H71 (Fig. 8C), which is more selective for disruption of Hsp90α/p23 interactions (30). Our results also are consistent with the observation that derivatives of Hsp90 inhibitor peptides sensitize cancer cells with overexpression of MDR to epirubicin (a class of anthracyclines that includes DOX) (46). Further studies will be required to determine the mechanisms of CP9 in reversal of MDR-1–mediated DOX resistance.

We noninvasively and repetitively monitored the inhibitory effects of CP9 in tumor xenografts in live mice by multimodality molecular imaging. BLI shows that CP9 selectively inhibits Hsp90α/p23 interactions relative to Hsp90α/p23 interactions (Fig. 5), and \(^{18}\)F-FDG PET/CT in the same cohort shows that CP9 inhibits glucose metabolism (Fig. 6). The selective inhibition of Hsp90α/p23 interactions and reduction in glucose metabolism in mice were consistent with the cell-culture results. However, CP9 did not decrease the expression of the Hsp90 client proteins significantly. Our results illustrate the challenges of transitioning...
from cell culture to animal studies in which the efficacy of lead compounds is limited by their tumor bioavailability (47).

Unified System Accelerated Drug Discovery, Mechanism Validation, and Lead Optimization in Living Subjects. In attempt to improve the potency of CP9, SAR studies were performed on the 62 analogs of CP9. The efficacy in degrading Hsp90 client proteins corresponds to the inhibition of BLI signals (Fig. S4). Furthermore, the most potent analog, A17, was more effective than CP9 in inhibiting Hsp90(α6/β)/p23 interactions and degrading Hsp90 client proteins in cell culture (Fig. S4B) but not in live mice (Fig. 6D). Nevertheless, the class of compounds that we have identified is distinct from PU-H71, which was used as a positive control for our experiments. Our data confirm the CP9 family as 2-(6-(trifluoromethyl)pyrimidin-2-yl)thio)acetamide–based Hsp90 inhibitors. However, further work in medicinal chemistry is necessary to optimize our lead compound in terms of potency, bioavailability, and other parameters important for therapeutic efficacy. Furthermore one could use some of the distinctive components of the chemical structure of CP9 further to derivatize chemically the compounds CP18 and CP19, which exhibited the lowest IC50 values. Our strategy allows rapid evaluation of such structural analogs using small quantities and will reduce the costs of compound syntheses.

In summary, we have identified and validated a class of Hsp90 inhibitors by coupling molecular imaging with HTS. Our work-flow allows rapid identification of cell-permeable lead compounds in cell culture, followed by monitoring of efficacy in live mice. This approach will accelerate significantly the development of the next generation of therapeutics aimed at inhibiting specific chaperone–protein interactions.

Materials and Methods

Chemicals, Enzymes, and Reagents. Coelenterazine was purchased from NanoLight Technology. Cell culture media, FBS, penicillin/streptomycin (P/S), and 4–12% (v/vol) gradient SDS/PAGE gels were purchased from Invitrogen. Puromycin hydrochloride and 17-AAG were purchased from Invivogen. Purine-scaffold Hsp90 inhibitor PU-H71 (13, 14, 48) was dissolved as 2.65 mM PBS stock and stored at −20 °C. The slow-kinetic RL substrate EnduRen (Promega) was dissolved in DMSO as 3.4 mg/mL stock and stored at −20 °C. Doxorubicin hydrochloride was purchased from Sigma.

Cell Culture. All cell lines used in this study were purchased from American Type Culture Collection and were cultured with their respective medium supplemented with 10% FBS and 1% P/S. 293T HEK cancer cells stably expressing Hsp90α(α6/β)/p23 split RL reporters (30) were maintained in Eagle’s Minimal Essential Medium medium and 1.5 μg/mL of puromycin. MCF-7 human breast adenocarcinoma cells and 2008 human ovarian cancer cells were maintained in RPMI medium. U87MG human glioblastoma cells, SKBr3 human breast carcinoma cells, 1975 lung cancer cells, HUH-7 and 4–4 liver cancer cells (received from Dean Felsher, Stanford University, Stanford, CA), PC-3 human prostate cancer cells, and V79 and V79/ADR hamster lung cancer cells (resistant to doxorubicin) were cultured with DMEM.

HTS of Small-Molecule Chemical Libraries Using 293T Cells Stably Expressing Hsp90α(α6/β)/p23 Split RL Reporters. To identify Hsp90 inhibitors the LOPAC from Sigma was used. HTS was performed at the Stanford High-Throughput Bioscience Center. 293T HEK cells (8 × 10^4) from columns 1–22 (E & K Scientific) expressing Hsp90α(α6/β)/p23 or Hsp90β(α6/β)/p23 split RL reporters were plated in each well of the 384-well white-bottomed plate in 60 μL of medium using the Wellmate matrix (Thermo Scientific) and were allowed to attach for...
Fig. 7. Efficacy of lead CP9 analog A17 in cell culture and in live mice. (A) Effect of A17, CP9, and 17-AAG on proliferation of 293T cells. 293T cells were treated with different concentrations of inhibitors for triplicate in 24 h before cell proliferation was determined by Alamar Blue assay. Emission signals were normalized to those of carrier control-treated cells and are expressed as mean ± SEM. (B) Effect of A17 on Hsp90α/p23 interactions in mice bearing 293T-FG xenografts. Mice were treated with four doses of A17 (80 mg/kg) after the establishment of baseline RL signals (Hsp90α/p23) and FL signals (cell proliferation) and were reimaged at the indicated time points. The net effect of A17 on Hsp90α/p23 interactions was determined as in Fig. 5C. Relative to carrier control-treated mice, A17 led to decreases in Hsp90α/p23 interactions at 43 h, but the differences were not statistically significant (P > 0.05). (C) Effect of A17 on Hsp90α/p23 interactions in mice bearing 293T-FG xenografts was determined as A. A17 did not lead to a significant decrease in Hsp90α/p23 interactions (P > 0.05 relative to carrier control-treated mice). (D) Ex vivo analyses of Hsp90 client proteins in excised tumors from B and C. The expression of pAkt, total Akt, and Raf-1 was determined by Western blotting as in Fig. 6D, and α-tubulin was used a loading control. A17 did not lead to significant decreases in Hsp90 client proteins (P > 0.05 relative to carrier control-treated mice).

Determinant of Efficacy of Lead Compounds in Disrupting Hsp90(α/β)/p23 Interactions. To determine the effect of lead compounds on disruption of Hsp90(α/β)/p23 interactions in intact cells, 3.5 × 10⁶ 293T cells stably transfected with split RL reporters (30) were plated in each well in the 96-well black-walled plate (Costar, Corning) and were allowed to attach for 24 h before treatment with different concentrations of the lead compounds for 24 h. Then 10 μg/mL of EnduRen (in 50 μL of cell-culture medium) was added to each well for 1.5 h, and RL activities were determined. BLI signals were normalized to that of the cell number for each well [determined by AlamarBlue assay (Invitrogen)] before normalization to carrier control-treated cells.

Western Blotting and Coimmunoprecipitation. To validate the mechanisms of the lead compounds and their analogs for inhibiting Hsp90(α/β)/p23 interactions, 293T cells stably expressing the Hsp90(α/β)/p23 split reporters were treated with 5 μM of CP1, CP9, CP18, or carrier (control) for 24 h. Cells treated with 2 μM of PU-H71 served as a positive control. Western blotting of Hsp70, pAkt, and total Akt, and co-immunoprecipitation of Hsp90(α/β)/p23 interactions were performed as described previously (30). The expression of Raf-1 was determined using rabbit polyclonal antibodies against Raf-1 (0.5 μg/mL (Abcam)).

³H-FDG and ³H-FLT Cell-Uptake Studies. To determine the downstream effects of lead compounds on glucose metabolism, 1.5 × 10⁶ 293T, 1975, and 2008 cells and MEFs were plated in a 24-well plate for 24 h before treatment with different concentrations of CP9 for 24 or 48 h and subsequent incubation with 1 μCi of ³H-FDG in 500 μL of medium for 1 h at 37 °C, as described previously (49). Cells treated with 2.5 μM of PU-H71 served as a positive control. The total counts in each sample were normalized to that of the dose added to each well and to the amount of protein and were expressed as mean counts dose⁻¹ microgram protein⁻¹ ± SEM. Likewise, the effect of CP9 on cell proliferation was determined using 1 μCi of ³H-FLT per well after 2 h of incubation at 37 °C (50).
Washout in 500 s sensitivity of drug-resistant V79/ADR cells to DOX. 

To determine if CP9 can inhibit proliferation of DOX-resistant lung cancer cells, V79 lung cancer cells and V69/ADR cells that are resistant to DOX were treated with DOX (0.31–10 μM) in the presence or absence of CP9 (8 μM) for 24 h before determination of cell number by Alamar Blue assay. (A) CP9 did not affect the sensitivity of drug-sensitive V79 cells to DOX. (B) CP9 partially restored the sensitivity of drug-resistant V79/ADR cells to DOX.

**Fig. 8.** Inhibition of cell proliferation of DOX-resistant V79/ADR lung cancer cells by CP9 and the Hsp90 inhibitor PU-H71 in cell culture. To determine if CP9 can inhibit proliferation of DOX-resistant lung cancer cells, V79 lung cancer cells and V69/ADR cells that are resistant to DOX were treated with DOX (0.31–10 μM) in the presence or absence of CP9 (8 μM) for 24 h before determination of cell number by Alamar Blue assay. (A) CP9 did not affect the sensitivity of drug-sensitive V79 cells to DOX. (B) CP9 partially restored the sensitivity of drug-resistant V79/ADR cells to DOX.

**Purified Hsp90(αi) Binding Assay.** To verify the binding of CP9 to Hsp90αi in vitro, a displacement assay using [3H]-17-AAG was performed. One microgram of purified Hsp90αi or Hsp90β was incubated with different concentrations of CP9 or DMSO carrier (control) in 50 μL of HBS-P+ binding buffer (Biacore) for 1 h on ice on a shaking platform. 17-AAG (final concentration of 200 μM) was used as a positive control. Duplicate samples were used for each condition. One micromolar of [3H]-17-AAG (final concentration of 0.5 μM) was added, and the mixture was incubated for another 30 min at room temperature. Unbound [3H]-17-AAG and inhibitors were removed using the 7-kDa Zeba desalt column (Thermo Scientific). The amount of [3H]-17-AAG that remained bound to Hsp90αi or Hsp90β was determined by scintillation counting.

**Displacement of [3H]-17-AAG Uptake by CP9 in HT29 Cells.** To determine if CP9 binds to cellular Hsp90, an uptake study of [3H]-17-AAG (Moravek Biochemicals) was performed. HT29 cells (1 × 105 in 500 μL of medium) were plated in each well of a 24-well plate and were allowed to attach for 24 h. Cells were incubated with 0.5 μM [3H]-17-AAG in the presence of 0.4–12.5 μM CP9 or carrier (control) for 1 h at 37 °C. PU-H71 (5 μM) was used as a positive control. This incubation was followed by two washes with 500 μL of PBS and 1 h of washout in 500 μL Hank’s Balanced Salt Solution (HBSS) to remove unbound [3H]-17-AAG. Cells were lysed on ice for 15 min in 300 μL of T-PER tissue extraction buffer in the presence of protease and phosphatase inhibitors (Thermo Scientific), and cell lysates were prepared for scintillation counting and protein determination. The total counts in each sample were normalized to that of the dose added to each well and to the amount of protein and are expressed as mean counts dose−1 microgram protein−1 ± SEM.

**Optical CCD Imaging in Live Mice.** Animal care and handling were performed in accordance with Stanford University Animal Research Committee guidelines. Mice were gas anesthetized using isoflurane (2% in 100% oxygen, 1 L/min) during all injection and imaging procedures and were kept at 37 °C. Mice were imaged using a cooled CCD camera (IVIS 200; Caliper Life Sciences). Tumor establishment and BLI of 293T cells stably expressing Hsp90αi/p23 split FL reporters and FL-EGFP in 7-wk-old female nude mice (nu/nu; Charles River) were performed as described previously (30). Baseline RL activity in the implanted tumors in live mice was determined by i.v. injection of 30 μg coelenterazine (in 150 μL of 5% ethanol/95% PBS) and image acquisitions of 3 min. After a 30-min wait for RL signals to decay, FL activities were determined by i.v. injection of 163 μg of α-luciferin (Biosynth, Itasca, IL) in 100 μL PBS with image acquisition of 10 sequences (15 s each) to obtain the peak maximum radiance. One set of mice (n = 5 per group) was injected i.p. with 80 mg/kg CP9 dissolved in 100% DMSO in a final volume of 0.1 mL. Another set of mice (n = 5) was treated with an equal volume of DMSO as control. At different time points after treatment, follow-up FL and RL imaging was performed. The maximum radiance of RL was divided by that of FL signals at each time point, before normalization to that of time 0 h for each individual mouse, and was expressed as average radiance ± SEM for each treatment group.

Mice were euthanized after the last imaging time points, and tumors were excised and homogenized in tissue extraction buffer in the presence of Halt Complete protease and phosphatase inhibitors (all from Pierce). Protein concentrations were determined by the Bio-Rad Protein DC assay. Expression patterns of chaperones in ten human tumor cell lines. Mice were gas anesthetized using isoflurane (2% in 100% oxygen, 1 L/min) during all injection and imaging procedures and were kept at 37 °C. Mice were imaged using a cooled CCD camera (IVIS 200; Caliper Life Sciences). Tumor establishment and BLI of 293T cells stably expressing Hsp90αi/p23 split RL reporters and FL-EGFP, baseline [18F]-FDG uptake in each tumor site for each mouse was determined by small-animal PET imaging using the Inveon PET/CT scanner (Siemens). Mice were placed on a custom-built mouse holder first for CT image acquisition (632 slices at 206 μm) that was used both for photon attenuation correction and image coregistration with PET image data for anatomical information. A static 5-min PET scan then was performed for [18F]-FDG activity and was reconstructed using the Ordered Subsets Expectation Maximization (OSEM) 2D algorithm (159 slices with 1.5-mm resolution). Region of interest (ROI) analysis was performed using the Inveon Research Workspace software. The maximum %ID/g upon normalization to injected dose was determined before and 43 h after CP9 treatment.

**PET/CT Imaging of Glucose Metabolism in Live Mice.** To determine the effects of CP9 on glucose metabolism in 293T xenografts stably expressing Hsp90αi/p23 split RL reporters and FL-EGFP, baseline [18F]-FDG uptake in each tumor site for each mouse was determined by small-animal PET imaging using the Inveon PET/CT scanner (Siemens). Mice were placed on a custom-built mouse holder first for CT image acquisition (632 slices at 206 μm) that was used both for photon attenuation correction and image coregistration with PET image data for anatomical information. A static 5-min PET scan then was performed for [18F]-FDG activity and was reconstructed using the Ordered Subsets Expectation Maximization (OSEM) 2D algorithm (159 slices with 1.5-mm resolution). Region of interest (ROI) analysis was performed using the Inveon Research Workspace software. The maximum %ID/g upon normalization to injected dose was determined before and 43 h after CP9 treatment.

**Data Analysis.** Each experiment was repeated at least three times, and results are expressed as mean ± SEM. Statistical differences were determined by Student’s t test using P < 0.05 as the cutoff point. HTS data were analyzed using Accelrys Assay Explorer (Accelrys Inc., San Diego, CA).

**ACKNOWLEDGMENTS.** We thank Drs. Tim Doyle and Frezghi Habte for scientific guidance and assistance with optical and PET/CT imaging and image analysis and for the use of the SCI2 Small Animal Imaging Service Center to generate data shown. This research was supported by National Institutes of Health Grant R01 CA082214 and National Cancer Institute In Vivo Cellular and Molecular Imaging Center P50 Grant at Stanford University (to S.S.G.), C.T.C. is the recipient of a Susan G. Komen Postdoctoral Fellowship.


Supporting Information

Chan et al. 10.1073/pnas.1205459109

SI Materials and Methods

Generation of 293T Cells Stably Expressing Heat Shock Protein 90 Isoform α/β/p23 Split Renilla Luciferase Reporter and EGFP-Firefly Luciferase Fusion Reporter. To monitor the effect of different heat shock protein 90 (Hsp90) inhibitors on cell proliferation, we used a second imaging reporter expressing Firefly luciferase (FL) and EGFP (EGFP-FL) under the control of an ubiquitin-C promoter (1). The effects of different inhibitors on Hsp90(α/β)/p23 interactions were monitored by Renilla luciferase (RL) imaging, and their effects on cell proliferation were monitored by FL imaging because their respective substrates (coelenterazine and d-luciferin) do not cross-react (2). This EGFP-FL reporter was introduced into 293T cells stably expressing Hsp90α/p23 or Hsp90β/p23 split RL reporters via lentiviral transduction as reported previously (1). Single-cell colonies were selected by plating cells at low densities (1,000–3,000 cells per 10-cm² dish) and FL imaging (1 min using a cooled CCD camera) upon addition of d-luciferin in PBS (0.225 mg/mL final concentration).

Screening of Structural Analogs of Lead Compound CP9. To identify more potent structural analogs of CP9, 293T cells stably expressing Hsp90α/p23 or Hsp90β/p23 split RL reporters and FL-EGFP fusion reporters were treated with 62 different CP9 analogs (Asinex) at 10 μM for 24 h in duplicate wells. CP9 (0.3–10 μM), 17-AAG (10 μM), and PU-H71 (5 μM) were used as positive controls in triplicate wells in 96 black-walled plates. The efficacy of the analogs in disrupting Hsp90(α/β)/p23 interactions and cell proliferation was monitored by RL imaging (2 h after the addition of EnduRen at 30 μM final concentration) followed by FL imaging (10 min after the addition of d-luciferin at 0.225 mg/mL final concentration) using a cooled CCD camera (1 min and 10 s for RL and FL imaging, respectively). RL signals were normalized to FL signals to account for the effect of the analogs on cell proliferation. Dose–response curves (six twofold serial dilutions) for the disruption of Hsp90(α/β)/p23 interactions in the stable cells also were generated for the top eight compounds (A17, A15, A29, A31, A39, A58, A61, and A65) and were compared with that of CP9. The effect of the CP9 analogs on the degradation of Hsp90 client proteins in 293T cells also was monitored by Western blotting as described in the main text. The IC₅₀ of the lead compound, A17, was determined by alamarBlue Assay.

Effect of CP9 on Proliferation of Doxorubicin-Resistant Lung Cancer Cells. To determine the effect of CP9 on proliferation of doxorubicin (DOX)-resistant V79/ADR cells, 3 × 10⁴ V79 and V79/ADR cells were plated in each well of a 96-well plate and allowed to attach for 24 h. Cells were treated with 0.31–10 μM DOX in the presence of 8 μM CP9 or PU-H71 or carrier (control) for 24 h. Cell proliferation was assayed by alamarBlue Assay as described in the main text.


Fig. S2. Degradation of multiple Hsp90 client proteins by CP9 in different cancer cell lines. (A) The effect of CP9 on expression of Raf-1, phosphorylated Akt (pAkt), and total Akt in 1975 (lung cancer), BT474 (breast cancer), and HuH-7 (liver cancer) cells and in normal mouse embryonic fibroblasts (MEFs) was determined by Western blotting as Fig. 3A. α-Tubulin was used as a loading control. (B) The effect of CP9 on mammalian thymidine kinase activity in 1975, 2008, and HT29 cells and in MEFs was determined by [3H]3-fluorodeoxythymidine cell-uptake studies 48 h after treatment as described in Fig. 4B. Results are expressed as mean counts-min⁻¹·microgram protein⁻¹·initial dose⁻¹ ± SEM. *P < 0.05 vs. carrier control-treated cells.
Fig. S3. Evaluation of the efficacy of CP9 analogs in disrupting Hsp90(α/β)/p23 interactions in 293T cells. To evaluate the efficacy of compounds that are structurally similar to CP9, 293T-FG cells stably expressing Hsp90(α/β)/p23 split RL reporters and EGFP-FL fusion reporter were treated with CP9 (0.63–10 μM) and its 62 different analogs (10 μM) or carrier controls for 24 h. Duplicate wells were used for each analog. Bioluminescence imaging (BLI) of the effects of CP9 and its analogs on Hsp90(α/β)/p23 interactions (complemented RL activities) was performed as in Fig. 1B. Hsp90(α/β)/p23 interactions were monitored by RL imaging, and cell proliferation was determined by FL imaging. (A) RL imaging of the inhibition of Hsp90α/p23 interactions by CP9 and 31 of its 62 analogs. A six-point dose–response curve was established for CP9 (rows A–F, columns 1–3). Duplicate wells were used for each analog concentration. PU-H71 and 17-AAG were used as positive controls at 10 μM in triplicate (rows C–F, column 12). Cells treated with 1% DMSO served as carrier control-treated (rows G and H, columns 1–5). Results from the 31 analogs are shown here. Some of the lead compounds (A14, A17, A23, and A29) are marked by dotted red circles. (B) CP9 and its analogs led to different levels of inhibition of Hsp90α/p23 interactions. To account for the effect of CP9 and its analogs on the inhibition cell proliferation, RL signals were normalized to FL signals, followed by normalization to signals of carrier control-treated cells; results are shown as mean ± SEM. The numbers next to each diamond (Hsp90α/p23) and square (Hsp90β/p23) denote the analog number (A1–A31). Dotted lines denote the level of inhibition of Hsp90(α/β)/p23 interactions by the parent compound CP9 at 10 μM.
Fig. S4. Characterization of lead CP9 analogs. (A) Time- and dose-dependent decrease in RL signals in 293Tα-FG and 293Tβ-FG cells by CP9 and its four most potent analogs. Cells stably expressing the Hsp90(α/β)/p23 split RL reporters and EGFP-FL fusion proteins were treated with indicated concentrations of CP9, its analogs, or carrier controls before BLI of RL signals upon addition of EnduRen. RL signals at each drug concentration and at each time point were normalized to that of carrier control-treated cells and expressed as mean ± SEM. (B) Dose-dependent decreases in Hsp90 client proteins Raf-1, pAkt, and total Akt in 293Tα/ p23-FG cells by CP9 and its analogs A17 and A29 were determined by Western blotting as in Fig. 3A. Cells treated with PU-H71 and 17-AAG (2.5 μM) served as positive controls. α-Tubulin was used a loading control.

**Table S1.** Chemical structures of the top 19 lead compounds (CP1–19) from the HTS of Hsp90 inhibitors

The structure of the known Hsp90 inhibitor PU-H71 is shown also.

**Table S2.** Structural analogs of the lead compound CP9

The compounds CP9 and A1-A62 that belong to the class of [2-(trifluoromethyl)pyrimidin-2-yl]thio)acetamides were selected rationally for structural activity relationship (SAR) studies.